

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: **001-36734**

Cipher Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)

2345 Argentia Road, Suite 100A
Mississauga, Ontario
L5N 8K4
(905) 602-5840

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Shares, no par value
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input checked="" type="checkbox"/>

Approximate number of holders of record as of the certification or notice date:
Common Shares, no par value: 3,923

Pursuant to the requirements of the Securities Exchange Act of 1934, Cipher Pharmaceuticals Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: January 13, 2017

Cipher Pharmaceuticals Inc.

By: /s/ Stephen Lemieux

Name: Stephen Lemieux

Title: Chief Financial Officer
